[Efficacity of treatment with lamivudine in two patients with severe reactivation of hepatitis B after withdrawal of chemotherapy]

Gastroenterol Clin Biol. 2000 Jun-Jul;24(6-7):671-4.
[Article in French]

Abstract

Reactivation of chronic infection is a serious complication during and especially after the withdrawal of cancer chemotherapy in hepatitis B virus carriers. Mortality is high, ranging from 4 to 20%. We report two cases of severe reactivation, after withdrawal of chemotherapy for chronic lymphocytic leukemia in one case and for a bladder tumor in the other. Recovery occurred with lamivudine therapy. Morbidity and mortality are common in these cases, especially when intensive chemotherapy and/or chronic hepatitis and/or precore mutants viruses are involved. Although lamivudine seems to be effective in these cases, prophylactic use has not been clearly defined and must be evaluated.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Aged
  • Antineoplastic Agents / administration & dosage*
  • Antiviral Agents / therapeutic use*
  • Female
  • Hepatitis B / complications
  • Hepatitis B / drug therapy*
  • Humans
  • Lamivudine / therapeutic use*
  • Leukemia, Lymphocytic, Chronic, B-Cell / complications
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • Male
  • Recurrence
  • Urinary Bladder Neoplasms / complications
  • Urinary Bladder Neoplasms / drug therapy

Substances

  • Antineoplastic Agents
  • Antiviral Agents
  • Lamivudine